EURONEXT-PAR$IPHA

Innate Pharma SA · Q4 2016 earnings

Q4 2016 earnings · · Investor relations

Headline financials

Total Revenue

€45M

Previous: €20.5M+119.7%
EPS (adj)

€0.29

Previous: €0.02+1061.3%
Net Income

€15.8M

Previous: €1.32M+1097.8%
Operating Income

€10.5M

Previous: €69K+15114.5%
Gross Profit

€16.7M

Previous: €3.35M+398.1%
R&D Expense

€28.4M

Previous: €17.2M+65.3%

Revenue & EPS history

Innate Pharma SA · Revenue · Quarterly

€45M

Q4 2016+119.7%vs Q4 2015

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 11 quarterly earnings reports

Historical avg

-0.6%

Avg return

Earnings day

-0.1%

Avg return

5 days after

-0.2%

Avg return

30 days after

27%

3 / 11 earnings

Positive

+13.5%

Q4 2019

Best reaction

-8.8%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026———
Q3 2025-2.4%-6.3%-3.1%
Q2 2024-4.2%-2.7%+37.6%
Q4 2023-2.9%+4.3%-1.8%
Q2 2023-3.9%-3.7%-3.0%
Q4 2022-8.8%-10.7%-11.8%
Q2 2022+2.8%+0.7%+13.5%
Q4 2021+2.6%+2.4%-23.3%
Q2 2021-0.6%-1.7%-7.3%
Q4 2020+0.0%+3.2%-5.1%
Q2 2020-2.6%+1.3%-5.1%
Q4 2019+13.5%+11.5%+7.3%
Q2 2019———
Q4 2018———
Q2 2018———
Q4 2017———
Q2 2017———
Q4 2016———
Q2 2016———
Q4 2015———
Q2 2015———
Q4 2014———
Q2 2014———
Q4 2013———
Q2 2013———
Q4 2012———
Q4 2011———
Q2 2011———
Q4 2010———
Q2 2010———

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro